- Home
- DTCK vs BTAI Comparison
DTCK vs BTAI Comparison
Compare DTCK & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTCK
- BTAI
- Stock Information
- Founded
- DTCK 1999
- BTAI 2017
- Country
- DTCK Singapore
- BTAI United States
- Employees
- DTCK N/A
- BTAI N/A
- Industry
- DTCK Farming/Seeds/Milling
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- DTCK Industrials
- BTAI Health Care
- Exchange
- DTCK Nasdaq
- BTAI Nasdaq
- Market Cap
- DTCK 26.5M
- BTAI 28.7M
- IPO Year
- DTCK 2023
- BTAI 2018
- Fundamental
- Price
- DTCK $0.97
- BTAI $0.57
- Analyst Decision
- DTCK
- BTAI Strong Buy
- Analyst Count
- DTCK 0
- BTAI 4
- Target Price
- DTCK N/A
- BTAI $5.00
- AVG Volume (30 Days)
- DTCK 35.7K
- BTAI 465.8K
- Earning Date
- DTCK 11-13-2024
- BTAI 11-14-2024
- Dividend Yield
- DTCK N/A
- BTAI N/A
- EPS Growth
- DTCK N/A
- BTAI N/A
- EPS
- DTCK 0.02
- BTAI N/A
- Revenue
- DTCK $159,836,000.00
- BTAI $2,276,000.00
- Revenue This Year
- DTCK N/A
- BTAI $247.03
- Revenue Next Year
- DTCK N/A
- BTAI $88.16
- P/E Ratio
- DTCK $48.58
- BTAI N/A
- Revenue Growth
- DTCK N/A
- BTAI 83.25
- 52 Week Low
- DTCK $0.76
- BTAI $0.50
- 52 Week High
- DTCK $1.75
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- DTCK 35.81
- BTAI 44.39
- Support Level
- DTCK $0.87
- BTAI $0.51
- Resistance Level
- DTCK $1.05
- BTAI $0.61
- Average True Range (ATR)
- DTCK 0.07
- BTAI 0.07
- MACD
- DTCK -0.02
- BTAI -0.01
- Stochastic Oscillator
- DTCK 28.88
- BTAI 27.15
About DTCK Davis Commodities Limited
Davis Commodities Ltd is an agricultural commodity trading company based in Singapore which specializes in trading of three main categories of agricultural commodities namely sugar, rice, and oil and fat products. It distributes agricultural commodities to various markets, including Asia, Africa and the Middle East. The company also provides customers of commodity offerings with complementary, ancillary services such as warehouse handling and storage and logistics services. The Company operates across four main segments: the sale of sugar, rice, oil and fat products, and others. Among these, the sale of sugar stands out as the primary revenue generator, contributing significantly to the company's overall income.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.